NCT06998719

Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC

A Phase II, Interventional Study of Neoadjuvant Durvalumab and Platinum-based Chemotherapy, Followed by Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab, in Borderline Resectable Stage III NSCLC (ACCESS)

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Bi Nan · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Phase II, interventional study of neoadjuvant durvalumab (MEDI 4736) and platinum-based Chemotherapy, followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab, in participants with borderline resectable stage III Non-small Cell Lung Cancer (NSCLC) (ACCESS)

Detailed description

This is a multicenter, Phase II, Chinese study assessing the efficacy and safety of neoadjuvant durvalumab and platinum-based Chemotherapy, given intravenously, followed by either surgery and adjuvant durvalumab or definitive CRT and consolidation durvalumab in participants with borderline resectable stage III NSCLC.

Conditions

• Non-small Cell Lung Cancer Stage III
• Borderline Resectable Carcinoma

Interventions

Type	Name	Description
DRUG	Durvalumab	Neoadjuvant durvalumab (MEDI 4736)and platinum-based chemotherapy, followed by either surgery and adjuvant durvalumab or CRT and consolidation durvalumab, in borderline resectable stage III NSCLC

Timeline

• Start date: 2025-07-01
• Primary completion: 2026-05-01
• Completion: 2027-12-01
• First posted: 2025-05-31
• Last updated: 2025-05-31

Locations

1 site across 1 country: China